To read our full disclaimer, click here.

Most investors have one label for this company, and it is two years out of date.

Failed launch.

The product got approved and then went nowhere. The stock lost more than 85% of its value in a year. A reverse split followed, then an emergency financing to clear the debt.

People filed it under broken biotech and moved on.

That label is the opportunity in my opinion.

Because what this is now is a turnaround, and it is already working. Management rebuilt the way the product reaches the customer, and the demand curve turned before anyone bothered to update the story. Volumes grew 51% year-over-year last quarter and set an all-time record in March. April beat March. Gross margins are 87%. The debt is gone.

Subscribe now

Here is what makes that interesting.

A turnaround that has already turned is a very different proposition to one you are still betting on. The evidence is in the numbers rather than in the pitch, and the market has not repriced it.

Then there is the second layer, and it is the part I like most.

Sitting on top of the commercial business are two late-stage programmes the market is currently valuing at zero. One goes after a market more than three times the size of the one the company sells into today, in a condition with no approved treatment anywhere in the world, and a partner is funding roughly 90% of the trial bill. The other already has an agreed path with the regulator.

Free optionality, on somebody else’s balance sheet.

So the category here is simple:

A microcap turnaround at the inflection point, with a partner-funded pipeline attached at no cost, in a stock still priced on the old story.

Here’s everything you need to know…

Read more

To read our full disclaimer, click here.

For three years, one number kept this stock in a cage.

The province that funds most of its business kept threatening to cut the rate it pays per bed. So investors treated the whole company as a coin flip on a government decision, and the multiple stayed on the floor.

This spring, the cut was cancelled.

Not deferred. Cancelled, and the rate maintained going forward.

The biggest overhang on the stock was just removed - replaced by a much smaller, capped headwind - and I don't think the market has repriced it.

Here is what makes that interesting.

The overhang lifted at the exact moment the business hit its inflection. Last quarter, revenue, EBITDA, margin, and net income all moved up together, with profit growing faster than revenue. That is operating leverage finally showing through, and margins are now closing in on double digits.

Underneath it: a profitable, dividend-paying business that already holds about 18% of its market, with plenty of room to keep taking share, a demographic wave at its back, and a balance sheet cleaner than it has been in years.

Subscribe now

I think the setup is asymmetric.

My base case points to a double from here, the bull case to more than 3x, and even my bear case limits the downside to roughly -25%.

Those are illustrative scenarios I use to frame the range, not forecasts, promises, or investment advice. The full assumptions behind each one are laid out below, and you should do your own work before drawing any conclusions.

Read more

Every deep dive you read here starts somewhere. Before the thesis, before the valuation work, before the risk section - there’s a list.

This is that list.

Each month going forward I’m now sharing my watchlist, the names I’m actively researching, where they sit in the pipeline, and what would move them up or knock them off.

Some of these will graduate to full deep dives. Some will fall away as I do the work. That’s the point - you’re seeing the funnel, not the finished product.

This month there are five names: a post-bankruptcy turnaround the market left for dead, a $5 million nano-cap with a founder who owns half of it, a botched pharma launch getting fixed by serious money, a quiet Canadian compounder about to show its operating leverage, and a medtech that just won a first-of-its-kind FDA approval.

Here’s what I’m watching, and why.

Read more

To read our full disclaimer, click here.

The Clinical Edge has a new name. It’s now Healthcare Stock Ideas.

Same person writing it, same research, same process - so if this email looks like it’s from someone new, it isn’t. It’s still me.

Here’s the honest reason for the change.

With the old name, I never got the reach or the discoverability this page should have had. “The Clinical Edge” just didn’t tell anyone what they were actually getting.

“Healthcare Stock Ideas” does. There’s no mistaking what this page is about now 😂.

And I think it deserves the reach…

Subscribe now

Let me start with where the page is at:

• 17 ideas published.

• 50% average peak return since publication.

• 6 of the 17 - 35% - up 75% or more at some point.

• The average idea is 169 days old. About five and a half months. The newest is nine.

But I lead with peak return for a reason.

This page is built for asymmetric setups, where the mispricing sits in the optionality and the biggest move usually comes early, before the crowd catches on.

Peak return is the honest headline for what this approach is designed to produce. And this is what micro-cap healthcare can do when the research is right.

That track record is why the rest of this matters.

Now the part I told you to stick around for…

I’ll be honest with you: this page has been priced well below the substacks in this niche performing at the level we are. That changes Monday.

From Monday, it’s $699 a year or $85 a month.

Until then it stays exactly where it is now - $400 a year or $50 a month.

After Monday, it will never be cheaper than it is today.

If you’ve been sitting on the fence, this is the moment. Subscribe or upgrade before Monday and you lock in the current price for as long as you stay subscribed, even after it rises.

Lock in Today's Price

The goal is simple going forward, and I’m writing it down here so you can hold me to it:

I want to become the number one healthcare newsletter on Substack.

To everyone already supporting the page - thank you. It’s your support that makes all of this possible.

Have a great weekend,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

In 1993, Peter Lynch wrote a column called “A Chicken’s Guide to Biotech.”

It was written for people who liked the idea of biotech but couldn’t stomach the risk.

The premise was simple: here’s how to get exposure to the sector without betting on some tiny lab that might blow up overnight.

A chicken’s way out.

I’ve read that column more times than I can count.

And here’s the funny thing.

Buried inside Lynch’s “play it safe” advice is the exact framework I use to think about healthcare microcaps today.

He just told his readers not to use it.

Let me show you what I mean…

Subscribe now

The Setup Hasn’t Changed in 30 Years

Lynch was writing in the middle of a biotech sell-off.

Investors had lost faith. They’d lost money.

And the roughly 225 publicly traded biotech companies of the era suddenly couldn’t raise a dime.

In his words, they could no longer “depend on the public generosity to keep them solvent.”

The new-issue market had shut down. The eager crowd of buyers had vanished.

So the cash-poor labs were forced into mergers, joint ventures, and licensing deals with richer partners - mostly the pharmaceutical giants.

It’s worth reading that twice, because it describes the biotech market almost perfectly right now.

A brutal drawdown. A frozen financing window. Dozens of small companies trading for less than the cash sitting in their bank accounts, forced to do deals just to survive.

To most investors, that’s a horror story.

I tend to see it differently.

Distress is what creates the mispricing. When good science is forced to sell itself cheaply, that’s often when the most interesting opportunities appear.

Lynch’s Chicken’s Way Out

Lynch’s first piece of advice was to buy the pharmaceutical giants.

The logic was sound. The giants had a problem - their blockbuster patents (Cardizem, Procardia, Ceclor) were expiring, and generics were eating into their margins.

But the biotech sell-off handed them a gift: the chance to buy cutting-edge science, with fresh patents, on the cheap.

So Lynch pointed readers toward names like Schering-Plough, which was spending $125 million a year on biotech R&D and had a licensing deal with Biogen for alpha interferon. It traded at about 15 times earnings, growing 15% a year.

Safe. Sensible. Diversified.

And it’s a perfectly reasonable way to invest.

It’s just not where the most dramatic outcomes tend to come from.

A large pharma giant that adds a promising biotech partnership doesn’t usually re-rate by a factor of ten.

The small company on the other side of that deal is a different matter.

Subscribe now

The Part Almost Everyone Skips

Lynch then offered what he called the “reverse chicken’s approach.”

Look at the biotech companies being absorbed by the giants, or the ones doing the major joint ventures.

His reasoning is the most important idea in the whole column:

When Roche spent $2.1 billion to acquire 60% of Genentech, Lynch said it was “a pretty good sign there’s some value left in the remaining 40%.”

That’s the heart of it.

A deep-pocketed pharma giant, with armies of PhDs doing due diligence, validating the science by writing an enormous check - and the public market still pricing the rest at a discount.

Lynch said it was the Roche-Genentech deal in September 1990 that finally convinced him the biotech industry was for real.

It took four months for Genentech to begin climbing, from $21 to $39.

This is close to how I think about The Clinical Edge.

Let the giants and the specialists validate the science. Then look for the small, overlooked company where the market’s story still hasn’t caught up to the scientific reality.

Narrative dislocation. The market lags the science. That gap is the whole point.

The Real Blueprint: Amgen

The best part of Lynch’s column is the Amgen story, and it’s a masterclass in optionality.

Fidelity’s biotech analyst, Mike Gordon, spotted Amgen around 1989 and was begging the in-house managers to load up while it traded at $5 to $7.

When Amgen’s first real product, Epogen, got final FDA clearance, the stock hit $10.

By the end of 1991, it was $76.

Ten times your money in about two years.

But here’s the lesson Lynch wanted you to take away, and it’s one most investors get completely wrong:

“Just because the good news is already out doesn’t mean it’s too late to invest.”

Amgen roughly doubled again in 1991-92 - after it had already won its patent battles, after the FDA approval, after the “obvious” news was public.

The optionality didn’t disappear when the first catalyst hit. It carried on.

It’s a useful reminder that the instinct to sell the moment a thesis starts working is often the wrong one.

The Volatility Is Real

Lynch was honest about the pain, and it’s only fair to be the same.

Not long after Amgen reached $70, the entire biotech sector dropped - because one unrelated company failed an important clinical trial.

Amgen was dragged down in sympathy. $70 to $35. A $10 billion company cut to $5 billion, on news that had nothing to do with it.

In Lynch’s words:

“An investor in biotech shares has to have a strong stomach, and it helps to be farsighted as well.”

But what he says next is the part worth underlining, because it’s essentially a screen:

When the whole sector gets hit, look for bargains - “companies with share values close to their cash holdings.”

With one crucial filter to keep the risk contained.

Limit the search to companies that already have drugs on the market, or at least in clinical trials, with real revenue coming in.

Cash on the balance sheet. Real products. Actual revenue. Bought during a sector-wide panic.

Regular readers will recognise that, because it’s almost word for word how I screen for healthcare microcaps trading near or below their own cash.

Here is one here:

Lynch wrote the filter in 1993. It still works.

Subscribe now

Where I Personally Go the Other Way

The way Lynch closes the column is, more or less, the way the masses have always been advised on biotech.

It’s too volatile. Too complex. Leave it to the professionals. Buy a diversified fund and don’t try to pick the small names.

There’s nothing wrong with that advice. But it is what almost everyone is told - and when the whole crowd is funnelled toward the same safe options, the giants and the funds and the index, the small overlooked companies get left for dead.

That neglect is the opportunity.

So my strategy deliberately goes the other way. Into the undiscovered, unloved corner of healthcare the masses are steered away from.

But going against the crowd without protection is just recklessness with extra steps.

So I take the very things Lynch said to look for in biotech and turn them into my margin of safety:

• Cash on the balance sheet, a product on the market or in trials, and real revenue coming in - the exact filter Lynch laid out, so the downside is anchored to something tangible.

• Multiple shots on goal - pipeline diversity, platform technology, more than one way for the thesis to work.

• Real problems - genuine unmet medical need, a clear regulatory path, customers willing to pay.

• Founder-led teams with their own money on the line.

Then comes the part that ties it all together: how I actually build a position.

I start small. The initial position is deliberately modest - sized so that if the thesis is simply wrong, it does no real damage to the portfolio.

I only add as catalysts approach and the data backs up the story.

And once a position is working, I’m in no rush to trim it.

That combination - operating where the crowd won’t, but insisting on cash, revenue, optionality and alignment before I do, then starting small and adding into strength - is the margin of safety.

It’s what lets me take controlled positions in an area everyone else is told to avoid.

The Takeaway

Peter Lynch wrote a guide for people who were nervous about biotech.

But, for me, a far more interesting approach was sitting in the same column the whole time.

Buy good science during a panic. Insist on cash on the balance sheet, real products, and real revenue. Let the giants validate the breakthroughs. Hold through the volatility. And think hard before cutting a position the moment it starts to work.

Lynch’s column was the careful, conventional route - the one the masses are pointed toward.

My strategy takes the opposite path on purpose: into the small, overlooked names the crowd is told to avoid, with cash, revenue, optionality and alignment as the margin of safety, and small, controlled position sizes as the seatbelt.

That corner of the market - small and overlooked healthcare companies - is exactly where this newsletter goes looking each week.

The Clinical Edge exists to do that work: 2-4 healthcare microcaps a month with asymmetric risk-reward, multiple shots on goal, aligned management, and mispriced optionality.

Paid membership is available here:

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

The company I’m sharing today first appeared last week over on Multibagger Ideas - but it deserves a second look here, because I think it’s genuinely one of the more interesting setups I’ve come across in a while.

It’s a rare one. The kind where several boxes get ticked at once - boxes I almost never find stacked together:

• A genuine world leader - an estimated 60-71% of the global proton therapy market - in a structurally growing corner of cancer care

• Toll-bridge economics: every machine sold turns into a multi-decade service annuity, now more than half of a €1.6 billion backlog

• Double-digit revenue growth - €620 million in 2025, up 24% - with profitability guided to roughly double by 2028

• That same €1.6 billion backlog set against barely €500 million of market cap - over 3x the whole company, already under contract

• Founder-rooted and insider-aligned, through the holding structure that controls the ~20% reference shareholder

• A self-funding balance sheet - just €57 million of net debt and a live buyback

• And the one that makes it rare: a 31.3% stake in the world’s largest emerging supply of actinium-225 - cancer’s next-wave isotope - sitting in none of the guidance, with a second free option in astatine-211 behind it

The company is…

Read more

To read our full disclaimer, click here.

The track record so far:

• 16 ideas published.

• 47% average peak return since publication. Not the best one. The average.

• 6 of the 16 - 38% - up 75% or more at some point.

• Average idea is 155 days old. Five months. The newest is 26.

Below is a short thesis summary of my favourite 10 ideas in random order.

A few are free for everyone to read; most sit behind the paywall, where you also get every new idea as it’s published and ongoing coverage of all of them.

As a thank you, I’m giving away just two 25% discount codes on the annual plan - the first two subscribers to redeem them get the rate:

Claim now!

Stock 1

A telehealth infrastructure company building the regulatory and operational backbone that every distributed-healthcare business in America needs, in a market projected to grow from $6.3 billion in 2024 to $10.7 billion by 2033. The platform spans three verticals: a network of 3,000+ independent registered nurses operating under the company’s medical license, a franchise solution helping med spas and IV clinics navigate telehealth regulation, and its real growth engine - a direct-to-consumer platform that lets entrepreneurs launch a 50-state-compliant telehealth company for $5,000/month, with everything from GLP-1s to peptides, TRT, and hair loss running through it. Over 12,000 licenses have sold since launch, now live across all 50 states. Q1 2026 revenue hit a record C$24.9 million, up 449% year-over-year, while operating expenses collapsed from 36% to 9% of revenue and adjusted EBITDA margin expanded to 13.1% - the third consecutive quarter of margin expansion. Management reaffirmed full-year guidance of at least C$150 million in revenue. As regulation tightens across digital health, the compliance-heavy platform becomes more valuable, not less - the moat working exactly as designed.

Stock 2

A profitable, multi-segment healthcare company the market spent years valuing at less than the cash sitting on its balance sheet. The business is anchored by an exclusive professional sales and services relationship with a major imaging OEM - selling and servicing diagnostic equipment across the US - now contractually secured through 2030, removing the single biggest risk to the thesis. Roughly 87% of its IT-segment revenue is recurring, providing a defensive base, while deferred revenue (cash already collected for services not yet delivered) recently hit a record - future earnings effectively banked. After divesting its weakest subsidiary, core revenue is growing, gross profit is expanding, and losses are narrowing as the leaner cost structure flows through the P&L. The story has matured from a pure below-cash arbitrage into an operating turnaround: a debt-free, cash-rich microcap whose record backlog gives it a clear runway to convert demand into earnings, quarter by quarter.

Stock 3

A profitable medical device manufacturer that makes the precision-engineered powered surgical instruments - handpieces, drivers, and shavers with tolerances measured in microns - used to install orthopedic implants, rather than the implants themselves. For over a decade it has been the critical supplier to one of the world’s largest medical device companies, which accounts for roughly three-quarters of revenue. The market treats that concentration as a fatal flaw; the reality is that switching costs on an FDA-approved product line are enormous, customer relationships run for decades, and the supply agreement has now been extended for years, securing the core franchise. After co-developing a next-generation handpiece platform with that customer, the company has moved into full production, with a multi-month backlog providing real revenue visibility. The model throws off significant operating leverage - incremental volume runs through an existing ISO 13485-certified facility with minimal added investment - and recent results show it, with double-digit revenue growth, expanding operating income, and net income that quadrupled. A bolt-on machining acquisition added capacity, and a legacy equity stake in a surgical-robotics company - acquired by a major orthopedics player - delivered realized cash gains plus a long-term supply agreement that could make this the critical supplier to a top-tier robotic-orthopedics platform. It trades at a low-teens forward earnings multiple and a fraction of the sales multiple typical for medical device peers.

Stock 4

A single-product specialty pharma company whose drug is the only on-label therapy in the U.S. for protecting against the permanent hearing loss caused by cisplatin, one of the most widely used chemotherapy agents in oncology. The drug carries roughly 96% gross margins, so nearly every incremental sales dollar drops through a largely fixed cost base into operating leverage. The original pediatric indication built the company to its first ~$44.6 million in annual sales, but the real engine is the adolescent and young adult (AYA) and adult population - roughly ten times the size of pediatric - which is now outgrowing the pediatric base as adoption expands across testicular, cervical, and head-and-neck cancers. The field organization has scaled its prescriber target from ~1,300 to over 5,000, and the patient-support program is converting a high share of referrals into completed infusions. The company is now GAAP-profitable with positive operating cash flow, carries zero debt and a healthy cash position, and has delivered six consecutive quarters of sequential revenue growth. A patent settlement secures U.S. market exclusivity to at least September 2033, and an optionality stack sits on top of the core story: European launches through a partner, ongoing Japanese registration discussions, and a widening clinical evidence base in adult tumor types - none of which is yet in the revenue line.

Stock 5

A rare disease pharmaceutical company that acquires rights to orphan drugs - therapies for patient populations so small that Big Pharma can’t be bothered - and then does what the previous owners never did: actually invests in commercializing them. The model carries unusually attractive economics: 70–75% gross margins, high switching costs (once a pediatric patient is stable on a therapy, physicians don’t switch), strong reimbursement with few alternatives, limited competition, orphan-drug regulatory exclusivity, recession resistance, and operating leverage as a flat sales infrastructure scales across more products. The portfolio has grown to 10 commercial products plus a deep pipeline of late-stage assets, funded through disciplined, cash-financed acquisitions with no dilution. The company has now turned GAAP-profitable with EBITDA margins inflecting higher, on the back of a long streak of consecutive quarters of sequential revenue growth. Its newest approved drug landed an unexpectedly broad label - no age restriction - expanding the addressable population from a few thousand children to roughly 9,000–10,000 adults at ~$80,000 per patient per year, with patent protection running to 2044. A separate bolt-on product, the only FDA-approved treatment for a time-sensitive infant condition, was just relaunched through a streamlined specialty-pharmacy channel. Management is targeting the largest rare disease portfolio in the U.S. (13–14 products), a $200 million revenue run-rate exiting 2027, 50% adjusted EBITDA margins by 2028, and $500 million in revenue by 2030 - and has so far done what it said it would do.

Subscribe now

Stock 6

The operator of Canada’s largest network of dedicated chronic pain clinics - regulated medical facilities staffed by specialists, funded almost entirely (97–99%) by provincial government health insurance. This is a private provider of public health services, delivering hospital-grade pain treatment (nerve blocks, radiofrequency ablation, ketamine and lidocaine infusions, and newer high-margin procedures) in community clinic settings that give patients faster access while costing the system less. The demand is structural, not cyclical: one in five adults lives with chronic pain, specialist wait times can stretch 18 months, and clinic waitlists run into the thousands - a public system that simply cannot keep up with an aging population. Recent results show clear operating leverage, with revenue growing in the mid-20s percent while adjusted EBITDA nearly doubled as capacity utilization climbed past 80% across a right-sized clinic footprint. The company has now posted positive EBITDA for 27 consecutive quarters, carries minimal net debt with one of the cleanest cap structures on its exchange (no warrants, no convertibles), and trades at roughly half the EV/EBITDA multiple of comparable Canadian healthcare clinic operators. With acquisition financing secured and 10–12 targets under evaluation in a fragmented market, the CEO buying shares personally, and a buyback running, there are multiple independent paths to value: organic growth, geographic expansion into new provinces, higher-margin service mix, and accretive M&A.

Stock 7

A profitable, debt-free advanced medical-consumables company selling into hospitals across three areas - vascular access, advanced wound care, and surgical consumables - all built around reducing healthcare-associated infections. Its anchor products cover and protect IV line connections, addressing an enormous clinical problem: roughly 90% of hospital patients get an IV line, more than a billion are placed each year, and every one is a potential pathway for bloodstream infection that costs far more to treat than to prevent. The business runs at 58% gross margins - 500 to 1,000+ basis points above much larger med-tech peers - is completely debt-free with net cash worth roughly a third of its market cap, and is owned about 50% by insiders, with the board alone holding around half the shares. The model is land-and-expand: win an account through clinical evaluation, then spread product across units and buildings, an annuity-like consumables base reflected in 99% retention of its top-50 hospital accounts. The structural change is a shift from selling hospital-by-hospital to securing system-wide approvals at Integrated Delivery Networks - large health systems with hundreds of sites under one purchasing umbrella - including marquee wins at nationally known medical centers. Each network approval clears the institutional barrier once and then feeds years of facility-by-facility pull-through. Because new accounts start small and convert slowly, the customer base has been built ahead of the revenue, and the stock trades near 1x revenue while debt-free med-tech consumables peers with lower margins trade at multiples of that.

Stock 8

A multi-engine home-healthcare platform that keeps very sick patients out of the hospital by delivering the equipment and clinicians they need directly into their homes, paid a recurring monthly fee - mostly by Medicare - for as long as each patient stays on therapy, which for the sickest can run years. The core business places in-home ventilators for end-stage COPD patients, supported by respiratory therapists and proprietary adherence software, generating durable recurring revenue. Layered on top are three growth engines: a fast-growing sleep apnea franchise with printer-and-ink economics (rent the machine, resupply masks and tubing), tailwinded by GLP-1 adoption pushing more patients in front of doctors; a newly acquired maternal-health line (breast pumps) that plugs into the company’s nationwide insurance contracts to reach markets the target could never serve alone; and a supporting base of oxygen, airway-clearance, and clinical staffing that feeds hospital referrals. The real moat is the operational scaffolding underneath all of it - payer contracts in every state, billing and compliance systems that actually get paid, clinical technology - built over nearly two decades and hard to replicate, so each new product line rides on top without rebuilding it. Recent results showed ~20% revenue growth, record adjusted EBITDA, and free cash flow that more than doubled as the mix shifted toward less capital-intensive categories, all on a near-net-cash balance sheet with an active, renewed buyback. The biggest overhang of the prior two years - a tighter Medicare coverage standard for in-home ventilation - has shifted from active threat to improving setup, with the more objective new criteria arguably favoring scaled providers. It trades around 5x forward EBITDA while home-care and DME peers have historically fetched 8–10x.

Stock 9

A molecular diagnostics company that the market left for dead behind a misleading headline - reported revenue fell sharply after it lost Medicare reimbursement on one legacy test - while the core business underneath was quietly thriving. Having exited that test, it’s now a pure-play thyroid diagnostics company, with 100% of revenue from two proprietary thyroid cancer tests that help physicians avoid unnecessary surgery. The core franchise has been compounding at double-digit rates, driven by rising test volumes, more accounts, and higher revenue per test, while the shift to a thyroid-only model has expanded gross margins toward the mid-60s and pushed adjusted EBITDA margins higher. This is a profitable, cash-generating, debt-free business - it paid off 100% of its debt - not a cash-burning turnaround. The capital structure has been cleaned up: the two private-equity sponsors that control roughly 84% of the company voluntarily converted their preferred stock to common, giving up their liquidation preference - a clear signal they see the upside in the equity, not the safety of the preferred. Management has stated its intent to uplist to Nasdaq, which would open the door to institutional investors barred from the over-the-counter market, improve liquidity, and potentially bring analyst coverage. It trades at a low multiple of forward revenue while the thyroid diagnostics market leader trades many times higher, despite this company growing faster with strong margins. The risks are real - reimbursement exposure, concentrated ownership, and thin liquidity - but the business is executing on every leg of the thesis.

Stock 10

A nano-cap cancer diagnostics company that just quietly hit an inflection the market hasn’t priced in. It runs a CLIA-certified molecular and cytogenetic laboratory delivering academic-level diagnostic accuracy - every report reviewed by faculty-trained pathologists - to community oncologists who lack in-house testing, catching the diagnostic errors that generic reference labs miss. The model has two inherently recurring streams: pathology services (~90% of revenue), where onboarded oncology practices send biopsy and blood samples month after month with high switching costs from credentialing and insurance enrollment, and a faster-growing products division (~10%) selling proprietary reagent kits and assay panels that labs reorder as supplies deplete - at structurally higher (~60%) margins. After working through a billing disruption caused by a cyberattack on its clearinghouse vendor, the company turned positive on both EBITDA and operating cash flow for the first time in its history, while growing revenue ~30% year-over-year. Operating leverage is the story: revenue is climbing while operating expenses stay roughly flat, so each incremental test or kit falls heavily to margin - gross margins have risen toward the high-40s with management targeting 50%+, and the mix shift toward the higher-margin products division could reshape the margin profile as it scales to 20–25% of revenue. It trades at a fraction of the EV/Sales multiple of diagnostics peers, leaving room to re-rate on continued execution alone.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

It’s been a while since the last update on this company.

And it’s been a very choppy year.

Back in August, the original thesis was published at C$2.90. The stock ran past C$5 as the business executed quarter after quarter. Then the Q3 earnings call happened - management couldn’t clearly explain their own numbers, KPIs shifted mid-call, and the stock dropped 26% in a single session.

The slide continued into the new year, with the stock touching a low of C$2.39 at one point.

Then Q1 2026 earnings landed earlier this week.

The stock ran quickly up to C$5.34, before settling back down to C$4.86.

That brings our total return since the original thesis to roughly 68%.

But here’s what makes this situation interesting:

• The business never broke.

• Revenue this quarter grew 449% year-over-year.

• Third consecutive quarter of margin expansion.

• Operating expenses fell from 36% of revenue to 9%.

• Cash position strengthened.

• Full-year revenue guide of at least C$150M reaffirmed.

What’s interesting is what management is not doing - namely, taking analyst questions on earnings calls. Two quarters in a row now, no Q&A.

The numbers are loud enough that they can probably get away with the silence. For now.

The asymmetry from the original C$2.90 entry has compressed. But on the 2026 guide, the stock is still trading at a meaningful discount to telehealth peers.

Today’s company is...

Read more

To read our full disclaimer, click here.

In November, we published a thesis on a profitable healthcare company trading at 71% of cash per share.

In February, with the stock up 30%, we revisited after two key catalysts - a divestiture and a GE HealthCare contract extension - landed in rapid succession.

The stock is now up roughly 64% from our entry point.

Q1 2026 earnings, released May 15th, are the first operational data point under the evolving leadership structure. The thesis has played out as expected. But the easy part in my opinion is over.

Here’s what the numbers said, what they mean, and where the thesis stands today.

Subscribe now

Where We Started, Where We Are

A quick reset before the numbers, because context matters here:

• November 2025: $0.14 stock price, $24M market cap, $35M cash → trading at 71% of cash

• February 2026: $0.18 stock price, $31.67M market cap → trading at 91% of cash

• May 2026 (today): $0.23 stock price, $40M market cap, $38.5M cash → trading at ~104% of cash

The structural mispricing we identified is essentially closed. The stock now trades at roughly its cash value, which means the easy arbitrage - buying a profitable, operating business for less than the bank account - is gone.

What’s left is the operating business itself.

So Q1 matters more than any quarter we’ve covered so far.

It’s the first chance to see whether the operational thesis - that management can turn a record backlog into actual earnings - is real.

What Q1 Actually Showed

The headline number looks soft: revenue of $19.4 million, down 0.5% year-over-year.

That’s misleading. Once you back out the healthcare IT reseller VASO divested in November, the same comparison shows revenue up 4.8%, and gross profit up 5.8%.

That’s the cleaner read.

Three things stood out underneath the headline:

1. The GE segment is delivering exactly as the contract extension implied. Professional sales services revenue was up 6.1% year-over-year, driven by higher imaging product deliveries from GE HealthCare and a higher blended commission rate. This is the segment that was contractually secured through 2030 in December. The first full quarter under the extended agreement confirms the relationship is producing - not just preserved.

2. Deferred revenue grew to a record $39.5 million, up 11.6% year-over-year. This is the metric that matters most for the long-term thesis. Deferred revenue is cash collected for services not yet delivered - it represents future earnings already in the bank. An 11.6% increase against a roughly flat revenue line means the booking machine is accelerating faster than the conversion machine. That’s both the opportunity and the bottleneck we flagged in the original post.

3. Net loss narrowed to $887 thousand from $1.1 million. Modest, but moving in the right direction. Adjusted EBITDA also improved slightly, from negative $1.12M to negative $1.07M. The post-divestiture business is leaner, and the early signs suggest the trim is showing up in the P&L. Q1 is seasonally the weakest quarter for VASO - management explicitly reminded investors that they’ve historically been more profitable in the later quarters of the year.

The Cash Burn Looks Worse Than It Is

The line item that will spook a casual reader: $12.6 million in cash used in operating activities, against $566 thousand in the year-ago quarter.

Management’s explanation: timing.

Payments expected in March arrived in April, distorting the quarter-end snapshot. That’s consistent with the deferred revenue growth, and the May 8 cash balance of $38.5M tells you the cash position remains healthy.

Cash per share is still roughly $0.22 against a $0.23 stock price.

I take the timing explanation at face value for now, but it’s the kind of thing that becomes a problem if it repeats. Q2 will be the tell. If operating cash flow returns to near breakeven or better, this was noise.

If it doesn’t, the working capital story needs a harder look.

Subscribe now

The Real Concern: SG&A

The one number I’m watching closely is SG&A. It rose 2.6% to $12.7 million, despite the divestiture of an entire subsidiary that should have meaningfully reduced overhead.

Management’s breakdown: higher personnel and travel costs, plus higher consulting and accounting expenses, partially offset by savings from the IT divestiture.

Two ways to read that.

• The optimistic read is that VASO is investing ahead of expected growth - David Mueller building out infrastructure, the team gearing up to convert the growing deferred revenue base.

• The pessimistic read is that cost discipline is loose, and the divestiture savings are being absorbed by overhead growth before they ever reach the bottom line.

You don’t get a verdict on this from one quarter.

But it’s the number I’ll be triangulating against revenue and gross profit growth for the rest of 2026.

Updated Risk Profile

Where the original risks stand after Q1:

• GE Partnership Deterioration - Still eliminated through 2030. Q1 confirms the relationship is producing, with the segment growing 6.1%.

• Operational Improvements Don’t Materialize - Early but encouraging. Deferred revenue up 11.6%. Core revenue up 4.8% ex-divestiture. Net loss narrowing. The conversion of bookings to revenue is still the central question, and the answer won’t be clear until at least Q3.

• Macro Headwinds - Slightly elevated. Management explicitly cited “growing uncertainties in the general business environment” and called out US tariff policy as a risk factor in the forward-looking statements. The 87% recurring revenue base in the IT segment remains the defensive anchor.

• Continued Illiquidity - Still a $40M market cap on OTCQX. Anyone sizing a position needs to size it for the door.

• New risk: The valuation cushion is gone. When we first wrote about VASO, you were paying 71 cents for a dollar of cash, plus the operating business for free. At $0.23, you’re paying for both. That changes the risk-reward materially. The thesis no longer has the “cash is a floor” safety net it had in November.

Where I Stand

Six months ago, VASO was a profitable company trading below cash with two specific catalysts and a partnership question mark.

Today, the partnership is secured through 2030. The weakest subsidiary is gone. Core revenue is growing. Deferred revenue is at a record. The net loss is narrowing. Management has done what it said it would do, and the stock has responded.

What’s left is a different kind of bet. The structural mispricing is closed. From here, VASO is a small-cap operating turnaround that has to keep proving itself quarter by quarter. The deferred revenue base says the demand is there. SG&A discipline and the Q2 cash flow print will say whether management can convert it.

The next decision point is Q2 earnings - specifically whether operating cash flow normalizes and whether SG&A growth slows. If both happen against another quarter of deferred revenue growth, the thesis transitions from “mispricing closing” to “quality compounder at fair value,” and the position works for a longer hold.

If Q2 looks like Q1 on cash and SG&A, the asymmetry has tightened enough that taking the gain is the right move for me.

Either way, the original thesis worked. Now we find out what kind of company VASO actually is.

One Discounted Annual Subscription

This post is free. The original VASO thesis wasn’t - paid subscribers got it on November 18 at $0.14, before the 64% move you just read about.

The next idea is already in the pipeline. If you want it when it comes out, I’m putting out one discounted annual subscription code here:

Get 25% Off!

It’s 25% off, and it goes to whoever claims it first through the link above.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Six weeks ago I published a deep dive on a name almost nobody was talking about.

Today the stock is up roughly 66%, the company has just reported its first GAAP-profitable quarter (a milestone that was not on management’s calendar for 2026), and every leg of the original thesis is starting to show up in the numbers.

What I find more exciting than the move itself is that this is not the only name doing this right now.

Across the archive, several of the names we have covered over the past year are inflecting at the same time. Earnings prints are confirming theses. Operating leverage is starting to land. Optionality stacks are widening.

We may be on the verge of our first multi-bagger, and possibly more than one.

Upgrade Subscription

For paid subscribers below:

• The full Q1 update on this idea.

• The new numbers worth watching.

• What changed in the option stack.

• How the valuation looks after the move.

• And my updated view on the stock from here.

Read more

To read our full disclaimer, click here.

A profitable medical-consumables microcap spent the last two years signing up hospitals faster than its revenue could show it.

• 58% gross margins - 500 to 1,000+ basis points above its much larger peers.

• Completely debt-free, with net cash worth roughly a third of the market cap.

• A $4 million special dividend paid last quarter, and the cash balance still went up.

• 99% retention of its top-50 hospital accounts.

• Two system-wide approvals at major US hospital networks, one with more than 300 sites of care.

• Roughly 50% insider ownership, with the board alone holding about half the shares.

Yet it trades right around 1x revenue.

Upgrade Subscription

The reason comes down to a single quarter. The company just reported revenue down 15% year over year - a genuinely soft print - and the market took that as the whole story.

I think that’s the mistake. The quarter wasn’t a broken business, it was order timing. Management disclosed that sales and firm orders booked in just the first six weeks of the current quarter had already passed the entire prior quarter’s revenue.

So the downside here is a debt-free, cash-rich, high-margin business. The upside is what happens when one timing quarter stops being the headline.

That’s the asymmetry I look for.

The company is...

Read more

To read our full disclaimer, click here.

Most investors avoid microcap healthcare companies like the plague.

Too risky.

Too volatile.

Too many failed trials.

They'd rather chase the latest AI darling or buy another index fund.

But, if I could invest in only one strategy for the rest of my life, it would be finding asymmetric bets in healthcare microcaps.

Not because it's predictable.

But because it's where the biggest mispricings hide in plain sight.

Healthcare microcaps offer the purest form of asymmetric risk-reward in public markets.

When a $50 million biotech discovers a breakthrough treatment, it doesn't become a $60 million company.

It becomes a $5 billion company.

That's the kind of optionality most investors never see.

Subscribe now

The Edge Hidden in Plain Sight

Healthcare is different from every other sector.

In software, you're betting on adoption curves and network effects.

In healthcare, you're betting on scientific breakthroughs that can't be disrupted.

When a small company solves a real medical problem with a defensible solution, the market doesn't just reward it – it transforms it.

Think about Moderna pre-COVID. A $6 billion company that most investors ignored.

The mRNA platform wasn't sexy. The financials weren't pretty. The path to profitability was unclear.

But the optionality was enormous.

One pandemic later, Moderna hit a peak market cap of $185 billion.

That's not a fluke.

That's what happens when optionality meets opportunity in healthcare.

Why Most Investors Get This Wrong

The traditional value investing playbook breaks down in healthcare microcaps.

You can't screen for low P/E ratios – most don't have earnings.

You can't demand fortress balance sheets – R&D burns cash.

You can't avoid volatility – binary events move stocks 50%+ overnight.

Instead, you need to think like a venture capitalist with a public market toolkit.

Risk management isn't about avoiding volatility.

It's about controlling position sizes and maximizing optionality.

Small bets.

Huge potential outcomes.

Mathematical expectancy in your favor.

My Framework: Optionality Over Everything

Here's how I think about healthcare microcaps:

💡 Look for Multiple Shots on Goal

• Pipeline diversity across indications

• Platform technologies with broad applications

• Regulatory pathways that create locked-in advantages

💡 Focus on Real Problems, Not Imaginary Markets

• Diseases with genuine unmet medical need

• Clear regulatory pathways to approval

• Willing-to-pay customers (patients, insurers, health systems)

💡 Back Founder-Led Teams with Skin in the Game

• Management owns meaningful equity

• Track record of value creation

• Deep domain expertise, not just MBA credentials

💡 Find Narrative Dislocation

• Market story lags scientific reality

• Temporary setbacks create permanent discounts

• Catalyst-rich environments with binary outcomes

Position Sizing: The Key to Asymmetric Investing

Here's how I structure positions:

• Initial positions: 1-2% – Small enough that total loss doesn't matter

• Conviction adds: Up to 5% – As catalysts approach and data validates thesis

• Home runs: Let them run – When optionality hits, don't cap the upside

The math is simple: Lose 1x on the failures, make 10-100x on the winners.

I only need to be right 10-20% of the time to generate life-changing returns.

What This Newsletter Will Cover

Healthcare microcaps aren't for everyone.

They're volatile.

They're complex.

They require patience and conviction.

For every 1,000 microcap healthcare companies, maybe 1 or 2 have legitimate asymmetric potential with the right combination of science, management, and market opportunity.

That's why this newsletter exists.

I release investment theses of 2-4 healthcare microcaps each month that meet my criteria:

✅ Asymmetric risk-reward profiles
✅ Multiple shots on goal
✅ Experienced, aligned management
✅ Real problems worth solving
✅ Mispriced optionality

There are simply not enough of these opportunities out there, so we'll only focus on the absolute best candidates we can find.

You can upgrade here if you want to become a paid member:

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Thanks to all of the paid subscribers who’ve joined over the past few months and made this one of the fastest-growing healthcare-focused investment newsletters on the platform.

Subscribe now

We’ve now covered 15 different healthcare ideas - wound care microcaps, telehealth infrastructure platforms, specialty pharma pulling share from 20-year monopolies, surgical pure-plays, rare disease rollups, cash-backed biotechs, diagnostics turnarounds, government biodefense, Canadian chronic pain clinics, pediatric oncology, in-home ventilators, and antimicrobial testing labs.

Here's how I think about every name on the list:

• Invest before the crowd understands.

• Bet asymmetrically.

• Multiple shots on goal. The thesis shouldn’t depend on one thing breaking right.

• Hold through the messy middle. The best ideas rarely move in a straight line.

• Optionality over predictability.

Below is a short thesis summary for every single idea covered on The Clinical Edge to date.

A few of these are free for everyone to read - so if you’re not yet subscribed, this is your chance to see the quality of our work firsthand.

For those considering a subscription: you’re not just getting these 15 ideas. You’re getting continued coverage of every one of them, 2-4 new ideas every month, access to the full Clinical Edge Index tracking every pick in real time, and a new research portal coming soon making it even easier to follow and view all our research.

Annual subscriptions are $400/year - that’s $33 a month versus $50 on the monthly plan. Prices are going up later this year, so lock in today’s rate now:

Upgrade Subscription

I hope you enjoy today’s post…

Stock 1

A wound care microcap built around a proprietary low-frequency ultrasound platform used to treat chronic wounds. The model is razor-and-blade: place systems into wound care clinics, then collect high-margin consumables revenue every time a patient is treated. FY25 revenue grew 35% to $44.1M, adjusted EBITDA nearly doubled to $13.6M, gross margins hit 77.1%, and 624 systems were placed versus 374 in 2024. The miss came on the top line. Management had originally guided $48-50M before CMS cut skin substitute reimbursement by 90-95% mid-year, taking out a chunk of the customer base that ran skin subs alongside the company’s product. The product’s own reimbursement code was unaffected and even got a small bump for 2026. Debt was refinanced with a tier-one bank, Q4 interest expense fell from $2.7M to $603K, and a reseller channel that wasn’t in the original thesis grew to 32% of Q4 revenue. The 2026 setup turns on three questions: did consumables churn bottom in Q4, do reseller placements convert into recurring orders, and does the implied back-half acceleration in management’s +16-25% full-year guide actually arrive.

Stock 2

A Canadian-listed digital health platform that quietly built the regulatory and operational infrastructure every direct-to-consumer telehealth business in America needs. Telemedicine technology, 50-state physician oversight, 503A and 503B pharmacy networks, and a modular B2B2C product that lets entrepreneurs launch a nationwide telehealth brand in days rather than months. The original thesis was simple: this was Shopify-for-healthcare with regulatory moats that actually mattered, riding the GLP-1 wave alongside TRT, peptides, hair loss, and sexual health. Q3 revenue grew 132% YoY and the business posted its fourth consecutive profitable quarter, but the stock then sold off in a single session after management fumbled basic KPI questions on the earnings call. The underlying numbers held: roughly 887K cumulative orders since platform launch, $18.6M cash, no debt. Since then: a December at-home STI testing distribution agreement with 50,000 pre-orders, FY26 baseline revenue guidance of approximately $150M at 15-17% adjusted EBITDA margin, a $15M bought deal led by Canaccord, and a March strategic investment in a buccal semaglutide platform that, if validated, would enable needle-free peptide delivery through the inner cheek. The infrastructure moat is real. The communication question is what management has to keep proving.

Subscribe now

Stock 3

A specialty dermatology pharma launching a new oral rosacea treatment into a $1.2 billion market that one drug had owned for 20 years. The Phase 3 head-to-head data showed 61% greater inflammatory lesion reduction than the incumbent and 28% greater than placebo, with patent protection until 2039. The CEO owns more than 10% of the company. The strategic partner owns 42%. The entire 50-rep commercial team came from a predecessor specialty pharma that sold to Bausch for $2.5B in 2012. They already call on these dermatologists every day, so adding the new product required zero additional infrastructure investment. FY25 revenue came in at $61.9M (+10%), with the new product contributing $14.7M in its partial year, roughly 53,000 prescriptions filled, gross margins improving to 66.2%, and the company flipping to positive adjusted EBITDA. Payer access expanded from 54M commercial lives in May 2025 to 100M+ by year-end, and an April 2026 contract with the third major group purchasing organization pushed access to 85% of all US commercial lives. The lever now shifts from access to formulary adoption, and as that happens, reliance on the co-pay bridging program declines and brand profitability improves.

Stock 4

A precision medical device manufacturer that designs and machines the powered surgical handpieces used in orthopedic and spine procedures. Roughly 75% of revenue comes from a single customer (their largest), which sounds like a screen-killer until you understand it’s an FDA-regulated, micron-tolerance product line with switching costs measured in years and a relationship that just got extended through December 2028, with minimum purchase volumes locked in for 2026 and 2027. FY25 net income quadrupled to $9.0M on $66.6M of sales (+24%), and the entry point was paying for the existing business at a discount while getting a free option on the next-generation handpiece ramp and a position in a publicly-traded robotics company that was subsequently acquired by Zimmer Biomet. That acquisition generated $8.9M in cash plus a 15-year supply agreement opportunity if the robotic platform is commercialized. H1 FY26 revenue grew 17% to $37.2M, EPS of $2.07, gross margin recovered to 31% after a Q4 tariff-driven compression, and management completed the acquisition of a long-time machining supplier with ITAR registrations to secure capacity ahead of the next leg of growth.

Stock 5

A specialty pharma quietly building one of the largest rare disease portfolios in the United States. The playbook: acquire orphan drugs in markets too small for Big Pharma to bother with, then actually invest in patient support, payer access, and physician education. At the time of original coverage, the company had 8 FDA-approved products generating cash, 5 development candidates, 19 consecutive quarters of sequential revenue growth, and 18x forward earnings on a story that was inflecting toward 75% gross margins. Five months later, virtually every catalyst hit. The lead pipeline candidate (oral desmopressin for central diabetes insipidus) was approved with no age restriction, opening 9,000-10,000 adult patients on top of the original 3,000-4,000 pediatric estimate. FY25 revenue more than doubled to $80M. Q4 adjusted gross margin recovered to 73%, EBITDA margin hit 29%, and the company turned GAAP profitable. Management acquired an additional commercial product (the only FDA-approved treatment for infantile hemangiomas) for $14M cash, expanding to 10 commercial products and adding pediatric dermatology as a third commercial call point. New long-term targets: a $200M revenue run rate by end of 2027, 50% adjusted EBITDA margins by 2028, and $500M in revenue by 2030. Built primarily off existing assets without assuming any new business development.

Stock 6

A profitable, three-segment healthcare company that, at the time of coverage, was trading below its own cash balance. The market saw a sleepy OTCQX ticker. The pieces of the story: 87% recurring revenue in the IT services segment (network and managed services), an exclusive sales agency for one of the largest medical device companies in the world covering its diagnostic cardiology and cardiopulmonary equipment in specific US territories, and a proprietary cardiovascular device line. The thesis hinged on a new VP of Operations hired directly from the partner organization to fix a booking-to-revenue conversion bottleneck. Bookings were running ahead of recognized revenue and the operations team couldn’t process them fast enough. Two months after coverage, the partnership agreement was extended through 2030, eliminating the single biggest existential risk. The underperforming healthcare IT reseller was divested. FY25 revenue hit a record $89.1M with $9.3M of operating cash flow and cash up to $35.1M. A five-year-locked partner relationship, a clean balance sheet, and an operations leader from the partner side now positioned to actually convert the bookings backlog into recognized revenue.

Subscribe now

Stock 7

A molecular diagnostics microcap that became a thyroid-only business in 2025 after losing Medicare reimbursement for its pancreatic cancer test. The market saw a 29% headline revenue decline and moved on. What it missed: the thyroid business that remained, a dual-test platform combining a next-generation sequencing oncogene panel with a microRNA expression classifier used by oncologists and endocrinologists to determine whether thyroid nodules require surgery, was growing 22% on a pro forma basis with 62% gross margins and roughly $4M in run-rate net income. At the time of original coverage, the entire business traded at 9x earnings and 1x revenue. Two healthcare-focused private equity firms controlled 84% of equity. Six weeks later, every piece of optionality was in motion: 2025 thyroid revenue grew 21% to roughly $35M, 2026 guidance set at $40M (+16%), all preferred stock was converted to common (the PE sponsors voluntarily gave up their liquidation preference), 100% of debt was paid off in December, and management formally announced intent to pursue a Nasdaq uplisting in 2026. FY25 thyroid volumes grew 13%, average revenue per test rose 5%, DSO dropped 19%, and the clean balance sheet now supports both organic acceleration and the relisting path.

Stock 8

A surgical products company that just made a decisive strategic pivot. Management shut down an unprofitable wound care services segment to focus entirely on what was working: an activated collagen product for tissue closure, a no-rinse antimicrobial surgical irrigation solution, and a small but growing bone fusion line. The company crossed $100M in trailing revenue with 93% gross margins, +22% YoY growth, and EBITDA expanding faster than revenue thanks to a 400+ contracted distributor network leveraging a small internal sales team. The pipeline added a free option: a synthetic injectable bone adhesive with FDA Breakthrough Device Designation, 40x stronger than calcium phosphate per preclinical data, targeting 100,000+ peri-articular fractures annually with a Q1 2027 launch planned. FY25 confirmed the operating leverage thesis. Revenue $103.1M (+19%), gross margin 93%, adjusted EBITDA up 86% to $17M, the discontinued segment is fully wound down, and an Innovative Technology contract with a major group purchasing organization opens 1,800 new facilities in 2026. Q4 was noisy on the surface (5% reported growth distorted by a hurricane comp; 13% adjusted) and the debt balance went up rather than down. The base business is fine. The refinancing window opens in April 2026, the bone adhesive program remains on track, and whether the next 12 months reaccelerate growth back into the high teens is the central question.

Stock 9

A nano-cap cancer diagnostics company that just hit its operational inflection point. Q3 2025 was the first quarter in its history with positive adjusted EBITDA ($469K), positive operating cash flow ($285K), and revenue growth of 30% YoY. Two revenue streams, both inherently recurring: a CLIA-certified molecular and cytogenetic lab serving community oncologists who lack in-house testing capability (roughly 90% of revenue, sticky monthly oncology test volume), and a Products division selling proprietary reagent kits and assay panels (10% of revenue, growing 15-20% quarterly at roughly 60% contribution margins). Gross margins climbed from 43% to 46% during 2025, with management targeting above 50% by mid-2026. The Change Healthcare cyberattack disruption that had hammered collections through 2024 was fully resolved, billing normalized, and the company moved from cash-strapped to self-funding. At 1.6x EV/Sales versus diagnostic peers at 3-5x, this was overlooked optionality on a recurring revenue platform with structural operating leverage. Preliminary FY25 results landed at $24M revenue (+30% YoY), Q4 adjusted EBITDA of $0.95M, and full-year operating cash flow of $688K. At the current valuation gap to peers, the re-rate likely has further to run if execution continues.

Stock 10

A specialty life sciences company that two years ago was left for dead. Manufacturing failures, regulatory scrutiny, and a balance sheet drowning in acquisition debt. The company quietly transformed itself into a cash machine. Two engines: Medical Countermeasures (anthrax, smallpox, botulism, and Ebola products sold to BARDA, the Department of Defense, and the Strategic National Stockpile) and a leading naloxone franchise. At the time of original coverage, the YTD swing was striking: net income flipped from negative $159M to positive $107M, SG&A was cut roughly in half, net leverage fell from 3.3x to 2x, and cash nearly tripled. International MCM jumped from the mid-teens to 34% of segment revenue. FY25 closed with $205M adjusted EBITDA (above guide), $110M of debt paid down, $171M operating cash flow (+53%), and $87M adjusted net income. Q4 was ugly. Revenue declined 24% on the government shutdown hitting naloxone sales to public-interest customers and segment gross margin collapsed to 6%. The 2026 guide implies a roughly 30% EBITDA step-down, partly because a $60M one-time international order doesn’t repeat and partly because management is reinvesting in growth. Real catalysts since the update: a $54M smallpox immunoglobulin contract from ASPR, a $140M CAD multi-product Canadian biodefense agreement, a refinanced term loan with OrbiMed (interest down 200bps, maturity extended to April 2031), a $34.5M Japanese encephalitis vaccine manufacturing partnership with US distribution rights, and a multi-year manufacturing agreement worth roughly $50M to support a Type 1 diabetes program. The turnaround happened. Whether the pivot to growth materializes is the harder bet.

Stock 11

A pre-revenue biotech whose entire existence rests on solving the most important unsolved problem in cancer biology: drugging mutant p53. p53 is the “guardian of the genome.” When it works, it detects DNA damage and triggers cancer cell death. When it breaks, cancer runs unchecked. It’s mutated in more than half of all human cancers, and for 40 years the field has considered it undruggable. The lead candidate is a first-in-class small molecule designed to bind a specific mutation-induced pocket in the p53 Y220C variant and structurally restore the protein’s normal function. Phase 2 PYNNACLE data: 34% overall response rate across 103 evaluable patients (median three prior lines of therapy), 46% in ovarian cancer, 79% disease control rate, with a clean safety profile. FDA Fast Track since 2020, Orphan Drug Designation March 2026, NDA filing target Q1 2027. Patents through the 2040s. Zero late-stage competition - the closest prior attempt failed Phase 3 in 2022. At the time of original coverage, the company had $112.9M in cash against a market cap roughly $30M lower. The entire pipeline traded at negative enterprise value. Single-asset binary biotech, cash through Q2 2027, probability-weighted expected value roughly 10-12x the current market cap on illustrative scenarios.

Subscribe now

Stock 12

Canada’s largest dedicated chronic pain clinic network, operating regulated medical facilities across Ontario and Alberta where pain specialists deliver injections, nerve blocks, radiofrequency ablation, ketamine infusions, and newer procedures including an injectable osteoarthritis treatment for chronic knee pain. 97-99% of revenue is government-funded through provincial health insurance programs. Recurring, payer-stable, with structural demand that isn’t going away (1,200+ patients on a single clinic’s waitlist; 18-month wait times for pain specialists in some markets). Q3 2025 revenue grew 26% to $22.1M with adjusted EBITDA nearly doubling to $1.5M as capacity utilization climbed from 73% to 84%. 27 consecutive quarters of positive EBITDA. Net debt under $2M, no warrants, no convertibles, no messy capital structure. The CEO has been buying personally, the company is buying back stock through its NCIB, all outstanding warrants have been retired, and management has 10-12 acquisition targets under active evaluation with bank financing already secured. The stock trades at roughly 5x trailing EV/EBITDA versus comparable Canadian healthcare clinic operators at 7-11x. The simplest re-rate to the low end of the peer range implies meaningful upside. To the middle of the range, more than a double. And that’s before the acquisition pipeline does any work.

Stock 13

A specialty pharma with a single product. But it’s the only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric cancer patients. A real clinical breakthrough in a category where oncologists have spent decades watching children lose their hearing as the price of curative chemotherapy. FY25 net product sales grew 51% to $44.6M, with Q4 revenue +75% YoY and five consecutive quarters of growth. The balance sheet was transformed during 2025. More than $42M in equity raised, all debt fully redeemed, year-end cash of $36.8M, zero debt. A patent litigation settlement extends generic-free runway to at least September 2033. The real story from here isn’t the existing pediatric business. It’s the adolescent and young adult market, which is roughly 10x the size of the pediatric indication where cisplatin use is far more common. A large community oncology practice has already added the product to formulary, the field force has been expanded for the first time in years, top-3 payer reimbursement is running at 95-100%, and a European partner is planning 8-10 launches in 2026 (UK and Germany already live). Positive Phase 2/3 results in Japan support a registration strategy in another major market. Operating expense steps up sharply in 2026 ($35M to $50M) as the company invests in the AYA expansion. Roughly 19% of the market cap is backed by net cash, before any credit for the 10x market expansion in front of it.

Stock 14

A multi-engine in-home medical equipment platform. The company keeps very sick patients out of the hospital by setting up clinical equipment in their living rooms and getting paid a monthly Medicare rental fee for as long as therapy continues. Four pieces: in-home ventilators for end-stage COPD patients (51% of revenue, multi-year retention, proprietary adherence software), PAP devices and resupply for sleep apnea (printer-and-ink economics, with GLP-1 adoption creating a real diagnostic tailwind as more patients sit in front of doctors), maternal health (a 2025 acquisition added breast pumps and related products plugged into a nationwide insurance footprint that the acquired business could never have reached on its own), and a smaller oxygen, airway clearance, and hospital staffing business. FY25 revenue grew 21% to $270.3M with record adjusted EBITDA of $61.4M (22.7% margin), and company-defined free cash flow more than doubled to $28.1M. Balance sheet is essentially net cash. The biggest overhang of the last two years, a National Coverage Determination update for in-home non-invasive ventilation, has shifted from active threat to improving setup, with 100% appeal success at the administrative law judge level and January 2026 reportedly one of the strongest setup months in company history. 2026 guidance: $310-320M revenue (+17% ex-M&A), $65-69M adjusted EBITDA. Active buyback just renewed for 2026.

Stock 15

A Canadian regulated antimicrobial and biofilm contract testing lab serving medical device manufacturers, pharmaceutical companies, and biotech sponsors who need to satisfy FDA, Health Canada, and European regulators that their devices don’t grow dangerous biofilms. The work is required (not discretionary), methodology-heavy, and accreditation-dependent. Once a client validates a test method with the lab and submits it to a regulator as part of a device file, switching means redoing the validation work and re-justifying it. FY25 revenue more than doubled to C$4.53M (the legacy lab grew 59% organically; the rest came from a 2024 acquisition that added analytical chemistry and GMP microbial testing into the platform). Gross margin 52.9%, adjusted EBITDAS up 238% on 107% revenue growth, profitable in 3 of 4 quarters with Q4 closing the year at a 22% EBITDAS margin. Net cash on the balance sheet covers roughly 12% of equity value. On April 14, 2026, the company began trading on the OTCQB. US capital can now access the stock without friction for the first time. Free optionality on a proprietary silver-based antimicrobial IP platform, a research-grade product line that is the only commercially validated tool for what it does, an enhanced 35% refundable Canadian R&D tax credit just substantively enacted, and an active M&A pipeline ranging from tuck-in to potentially transformational. Sweet spot of investable and under-followed.

Subscribe now

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Note: The scenarios, probabilities, and potential return estimates discussed in this post reflect my personal assumptions and framework for thinking about risk-reward. They are not guarantees, predictions, or investment advice. Always do your own research.

Every medical device that goes inside a human body has to pass a specific set of tests.

Catheters. Implants. Injectables. Surgical mesh. Wound care products.

The question regulators want answered is simple: can bacteria colonize this device and form biofilms?

The FDA requires testing. Health Canada requires testing. European regulators require testing.

It’s a regulatory checklist item, not a “nice to have.”

And the testing isn’t simple.

It takes custom methodologies, specialized equipment, accredited quality systems, and years of relationship-building between client and vendor. Once a client validates a method with a particular lab, switching means redoing the work and re-justifying it to the regulator.

In North America, only a handful of labs are qualified to do this work at the highest level.

One of them is a microcap that’s just doubled its revenue, was profitable in three of four quarters in 2025, sits on a net cash balance sheet, and started trading in the United States for the first time a few weeks ago.

Upgrade Subscription

Here’s what makes this interesting:

• Required spend, not discretionary spend. Customers don’t have a choice. Antimicrobial and biofilm testing is a regulatory line item on the path to FDA clearance.

• Real operating leverage. Adjusted EBITDAS grew 238% on 107% revenue growth in FY2025. The ratio matters more than the absolute numbers at this scale.

• Net cash balance sheet. Net cash covers roughly 12% of the equity value, with no externally imposed financial covenants and a current ratio of 5.79.

• Profitable in three of four quarters in 2025. Q4 closed the year with an Adjusted EBITDAS margin of 22%.

• Active M&A pipeline. Management has flagged tuck-in, bolt-on, and potentially transformational acquisitions actively under evaluation for 2026.

• Free optionality. A proprietary antimicrobial IP platform, a research-grade product line, and a recently enhanced refundable R&D tax credit. None of that is reflected in the current financials.

• Listing catalyst. US capital can now access the stock without friction for the first time.

My rough scenario assumptions (not predictions, just how I’m framing the risk-reward):

• Stagnation / deceleration (~30% probability): Organic revenue growth slows to single digits, M&A pipeline stalls, the operating leverage thesis fades. Stock drifts back toward C$0.13-0.15. Downside: ~25-35%.

• Base case (~50% probability): 25-30% revenue growth in 2026, Adjusted EBITDAS margin expands to 13-15%, market re-rates to ~10-12x forward EBITDAS as US investors discover the listing. Upside: ~75-100%.

• Bull case (~20% probability): Tuck-in M&A executes accretively, organic growth holds in the 40%+ range, EBITDAS margin reaches 18-20%, multiple expands toward US-listed CRO peers in the 12-18x range. Upside: ~3-5x.

• Probability-weighted expected return: roughly 80-130% from current levels against limited downside given the cash floor and the operating earnings already on the table.

The company is...

Read more

To read our full disclaimer, click here.

The company I'm sharing today is a rare case that checks the following boxes:

• High-quality, recurring revenue from medical equipment rentals to chronically ill patients

• 21% revenue growth in 2025, with record Adjusted EBITDA and free cash flow that more than doubled

• Near-zero net debt, active board-authorized buyback - just renewed for 2026

• The 2025 buyback was executed at an average price 38% below where the stock trades today

• The biggest regulatory overhang of the last two years just shifted from active threat to improving setup

• Multiple growth engines layered on top of the core: sleep/resupply compounding, maternal health scaling, tuck-in M&A optionality

• ~$357M market cap, limited sell-side coverage (the sweet spot of investable and under-followed)

• Trades at ~5.3x 2026 EBITDA while healthcare services peers fetch 8-10x, with management guiding another year of strong growth

Upgrade Subscription

I like each of these properties a lot, but rarely find them all in one stock.

After watching it trade sideways under a regulatory cloud for two years, the Q4 print and 2026 guidance confirmed the story is finally moving in the other direction - and the market is only starting to reprice.

Read more

To read our full disclaimer, click here.

I wrote up SANUWAVE (SNWV) in August at $35.

It’s $17.50 today.

Before getting into the update, that’s where this starts - down 50% from the original call.

However, the business itself had its best year ever.

So why is the stock cut in half? And more importantly, is the thesis from here still intact?

Subscribe now

The numbers

• Revenue: $44.1M, up 35%

• Adjusted EBITDA: $13.6M, up from $7.2M

• Gross margin: 77.1%

• Systems sold: 624 (vs 374 in 2024)

• Consumables: $25.5M, 58% of revenue, up 27%

• Q4 revenue: $13.4M (record), 255 systems placed

Worth flagging: FY revenue of $44.1M came in well below the $48–50M management guided to when I originally wrote this up.

That’s a miss, not a beat.

What broke

CMS cut reimbursement for skin substitutes and allografts by 90–95% in 2025 and started auditing aggressively. Some providers got hit with nine-figure clawbacks. Management called it a grenade in a fish pond.

UltraMIST wasn’t the target - its reimbursement code actually got a small bump for 2026. But a chunk of SANUWAVE’s customer base ran skin subs alongside UltraMIST, and when skin subs blew up, those customers did too. Some pulled back on volume. Some closed.

The damage shows up in consumables, which is the number that matters in a razor-blade model. Full year consumables +27%. Q4 consumables +10.6%. That’s a sharp deceleration. And 168 active systems were discontinued in Q4 alone, about 13% of the installed base.

Net active systems still grew - 1,236 to 1,292 - but only because they placed 255 new ones on top of the churn. That’s running hard to move a little.

Subscribe now

What I got wrong

No point pretending otherwise:

• I underwrote 50%+ growth as sustainable. 2026 guidance is now 16–25%. Different business.

• I expected the debt paid off by year-end 2025. It was refinanced, not eliminated - ~$21M still on the balance sheet.

• I didn’t model an industry-adjacent reimbursement shock. Nobody did, but that’s not an excuse, it’s a lesson.

What’s genuinely better

A few things cut the other way and deserve credit:

• Reseller channel. 32% of Q4 revenue, up from 26% in Q3. Former skin-sub distributors picking up UltraMIST because it has a clean reimbursement path. Higher operating margin because SANUWAVE doesn’t carry the sales cost. This wasn’t in the original thesis.

• Debt cost. Refinanced with JP Morgan. Interest expense dropped from $2.7M in Q4 2024 to $603K in Q4 2025.

• Manufacturing costs stepping down starting Q1 2026.

• New customer formation. Management’s “baby elephants” - small new wound care groups emerging from the dissolution of old ones, actively seeking UltraMIST. Early, but real.

Subscribe now

Where I land

• The business is demonstrably stronger than a year ago on revenue, profitability, balance sheet, and distribution.

• The growth trajectory I underwrote is not the growth trajectory I’m getting.

Those are both true.

What I don’t think is true: that the stock being down 50% means the pick was wrong.

The business didn’t fall apart. The industry around it did, and SNWV got caught in the downdraft despite its own reimbursement code being fine. That’s a real outcome, not a rationalization - but it also doesn’t erase the fact that I underwrote growth that isn’t showing up.

EV/EBITDA lands somewhere between ~9x on basic shares and ~19x fully loaded. The truth is in between. Either way, it's no longer the layup it was on the original thesis math.

Three things that decide whether this works from here:

1. Q1 consumables. Did the churn bottom in Q4 or is it still bleeding? Most important data point.

2. Reseller channel recurring pull-through. One quarter of strong reseller placements is a data point. Two quarters of recurring consumable orders behind them is a trend.

3. H2 2026 acceleration. Q1 guidance is +3–10%. Full year is +16–25%. That implies a big back-half pickup. If it doesn’t materialize, the deceleration is structural, not transitional.

Updating again after that print.

Thanks for reading,

Nico

Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.

To read our full disclaimer, click here.

Five months ago, we profiled a microcap rare disease company hitting commercial inflection at 18x forward earnings.

The pitch was simple: a growing orphan drug portfolio, margins headed toward 75%, five near-term FDA catalysts, and a stock priced like nothing was about to happen.

Here’s what’s happened since:

• The company’s biggest pipeline candidate received FDA approval and launched commercially within two weeks. The label came in cleaner and broader than expected - expanding the addressable market well beyond the original forecast.

• Full-year 2025 revenue more than doubled versus 2024.

• Q4 revenue grew 83% year-over-year.

• Adjusted gross margins recovered to 73%, confirming the prior quarter’s compression was temporary - exactly as we flagged.

• Adjusted EBITDA margin hit 29%, up from 18% a year ago.

• The company turned GAAP profitable.

• The portfolio expanded from 8 to 10 commercial products through a disciplined acquisition funded entirely with cash - no dilution, no debt.

• 2026 guidance calls for revenue exceeding $110 million with EBITDA margins above 30%.

• Management just set new long-term targets: $200 million revenue run rate by end of 2027, 50% EBITDA margins by 2028, and $500 million in revenue by 2030.

The stock is up 35% from our write-up.

But the fundamental story has arguably improved by more than the stock has moved.

Our original base case implied roughly 42% upside. Our bull case outlined nearly 200% upside over 2-3 years. With the catalysts now materializing, the updated setup may offer even more.

Let’s walk through what’s happened, what’s changed, and where the risk/reward sits today…

Read more

To read our full disclaimer, click here.

For decades, cisplatin-based chemotherapy came with a tradeoff oncologists couldn’t solve. The drug was one of the most effective tumor killers in the arsenal - but it also caused permanent hearing loss, especially in children. There was no approved way to protect patients’ hearing during treatment.

One company changed that.

Upgrade Subscription

It developed and commercialized the only FDA-approved product to reduce the risk of cisplatin-induced hearing loss in pediatric cancer patients. A genuine clinical breakthrough - and now a commercial story that’s accelerating fast.

Product sales grew from $29.6 million to $44.6 million in a single year. Q4 revenue hit $13.8 million - up 75% year over year. Management says the company delivered quarter-over-quarter growth in every quarter of 2025, and that momentum carried into 2026.

The debt is gone. All of it. The balance sheet is clean - $36.8 million in cash, zero debt.

And the real market opportunity? It’s about 10 times larger than the one they’re currently selling into.

The pediatric indication was just the entry point. The adolescent and young adult market - where cisplatin use is far more common - is where management is pointing the commercial engine now. A large community oncology practice has already added the product to formulary. New clinical studies are building the evidence base in adults. Europe is launching. Japan data came back positive.

The company just settled its only patent litigation. No generic entry until at least September 2033.

Here’s what I find interesting:

• Revenue acceleration: $44.6 million in 2025 product sales, up 51% year over year, with five consecutive quarters of growth

• Clean balance sheet: $36.8 million in cash, zero debt, after fully redeeming all outstanding obligations

• Market expansion: The AYA market is roughly 10x the size of the current pediatric indication

• Patent protection: Cipla settlement extends the generic-free runway to at least September 2033

• Global rollout: European launches underway through Norgine, Japan registration being pursued after positive trial results

The company is...

Read more

To read our full disclaimer, click here.

In early January, we published a deep-dive on a surgical products company with 93% gross margins, 22% revenue growth, and a pipeline product with FDA Breakthrough designation that the market wasn’t pricing.

The thesis was straightforward: you were getting a profitable, growing surgical business at half the peer multiple, with a first-of-its-kind bone adhesive as free optionality.

Then Q4 earnings dropped. And the stock kept falling.

• Revenue grew just 5% year-over-year.

• Operating income missed estimates by 66%.

• A noncash impairment charge hit the P&L.

• And the debt balance - which the original thesis expected to come down - went up instead.

The stock is now $18, down roughly 25% from our initial coverage.

But here’s the thing about optically messy quarters - sometimes the headline hides the progress.

• Full-year revenue crossed $100 million for the first time - $103.1 million, up 19%.

• Gross margins at 93%.

• Adjusted EBITDA nearly doubled to $17 million.

• Operating cash flow swung from essentially zero to $6.8 million.

• The money-losing THP segment is officially dead.

• And the company just secured a Vizient contract that opens 1,800 new facilities for its fastest-growing product.

The Q4 comp was distorted by a hurricane. The debt increase has a reason behind it.

And 2026 guidance of 13-17% growth - while decelerating - still represents the first formal revenue guidance in the company’s history.

The stock is cheaper today than it was when I wrote the thesis.

The question is whether it’s cheaper for the right reasons or the wrong ones.

Let me walk through what happened, what changed, and where the thesis stands...

Read more

To read our full disclaimer, click here.

Note: The scenarios, probabilities, and potential return estimates discussed in this post reflect my personal assumptions and framework for thinking about risk-reward. They are not guarantees, predictions, or investment advice. Always do your own research.

One in five adults lives with chronic pain.

Not a headache. Not a sore back after a long flight. The kind of pain that doesn’t stop - nerve damage, failed surgeries, degenerative spinal conditions, injuries that never fully healed. The kind that pulls people out of the workforce, off their feet, and into a cycle of opioid prescriptions because nothing else is available fast enough.

In Canada, the wait to see a pain specialist can stretch 18 months. In some cities, over a thousand patients sit on a single clinic’s waitlist.

The healthcare system can’t keep up. And one company built the infrastructure to fill the gap.

Upgrade Subscription

It operates Canada’s largest network of chronic pain clinics - regulated medical facilities staffed by specialists, funded almost entirely by government health insurance. Not a startup. Not a concept. A real business with real patients walking through the door every day.

Last quarter, revenue grew 26%. Adjusted EBITDA nearly doubled. Capacity utilization climbed to 84%. The balance sheet is clean - net debt under $2 million, no warrants, no convertibles, no messy capital structure. The company has posted positive EBITDA for 27 consecutive quarters.

And the stock trades at roughly 5x trailing EV/EBITDA.

For context, comparable Canadian healthcare clinic operators trade at 7-11x. Some well above that.

Here’s what makes this interesting:

• Valuation gap: 5x trailing EV/EBITDA vs. 7-11x for peers - at the low end of the peer range alone, that implies 44% upside. At 10x, the stock more than doubles.

• Growth trajectory: 26% revenue growth, 98% EBITDA growth, and management guiding for high single- to low double-digit organic growth ahead.

• Acquisition pipeline: 10-12 targets under evaluation, with financing already secured through National Bank.

• Insider conviction: The CEO is buying shares personally. The company launched a buyback. All warrants were retired. Management has said publicly they believe the stock is undervalued.

• Structural demand: 1,200+ patients on waitlists. 18-month specialist wait times. An aging population. This isn’t cyclical demand - it’s a healthcare system that structurally cannot serve the need.

I think the market is overlooking this one. It’s small, it’s quiet, and it doesn’t screen well. But the fundamentals have been improving for seven straight years, and the valuation hasn’t caught up.

The company is...

Read more